Xiao Yao, Xu Gang, Cloyd Jordan M, Du Shunda, Mao Yilei, Pawlik Timothy M
Department of Liver Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, China.
Department of Liver Surgery and Liver Transplant Center, West China Hospital of Sichuan University, Chengdu, China.
J Gastrointest Surg. 2022 Aug;26(8):1670-1678. doi: 10.1007/s11605-022-05337-6. Epub 2022 May 4.
There is a paucity of effective treatment options for advanced pancreatic neuroendocrine tumors (pNETs). Genome-wide analyses may allow for potential drugs to be identified based on differentially expressed genes (DEGs).
Oligo microarray data of RNA expression profiling of pNETs and normal pancreas tissues were downloaded from the Gene Expression Omnibus. Functional and pathway enrichment information of the DEGs was obtained using the Gene Ontology and Kyoto Encyclopedia of Genes and Genomes databases. Corresponding homologous proteins were analyzed and potential therapeutic drugs for pNETs were identified using the Connectivity Map and Drug-Gene Interaction Database.
Assessment of raw data from 12,610 pNET genes demonstrated that 1082 and 380 genes were upregulated and downregulated, respectively, compared with normal pancreas tissue. Upregulated pathways were associated with nitrogen metabolism (i.e., GABAergic synapse, and graft-versus-host disease), whereas downregulated pathways included C-type leptin receptor signaling pathway, pertussis and AMPK signaling pathway. In particular, the protein-protein interaction analysis revealed 10 upregulated hub genes (DYNLL1, GNB5, GNB2, GNG4, GNAI2, GNAI1, HIST2H2BE, NUP107, NUP133, and SNAP25) and 10 downregulated hub genes (CXCL8, F2, CXCL2, GCG, SST, INS, GALR3, CCL20, ADRA2B, and CXCL6). Using the Drug-Gene Interaction Database, candidate drugs for pNETs treatment included 3 EGFR inhibitors (canertinib, erlotinib, WZ-4-145), as well as other cell-signaling pathway inhibitors such as AG-592, acarbose, lonidamine, azacytidine, rottlerin, and HU-211.
Using available genetic atlas data, potential drug candidates for treatment of pNETs were identified based on differentially expressed genes. These results may help focus efforts on identifying targeted agents with therapeutic efficacy to treat patients with pNETs.
晚期胰腺神经内分泌肿瘤(pNETs)的有效治疗方案匮乏。全基因组分析可能有助于根据差异表达基因(DEGs)确定潜在药物。
从基因表达综合数据库下载pNETs和正常胰腺组织的RNA表达谱寡核苷酸微阵列数据。使用基因本体论和京都基因与基因组百科全书数据库获得DEGs的功能和通路富集信息。分析相应的同源蛋白,并使用连通性图谱和药物-基因相互作用数据库确定pNETs的潜在治疗药物。
对12610个pNET基因的原始数据评估表明,与正常胰腺组织相比,分别有1082个和380个基因上调和下调。上调的通路与氮代谢相关(即γ-氨基丁酸能突触和移植物抗宿主病),而下调的通路包括C型瘦素受体信号通路、百日咳和AMPK信号通路。特别是,蛋白质-蛋白质相互作用分析揭示了10个上调的枢纽基因(DYNLL1、GNB5、GNB2、GNG4、GNAI2,、GNAI1、HIST2H2BE、NUP107、NUP133和SNAP25)和10个下调的枢纽基因(CXCL8、F2、CXCL2、GCG、SST、INS、GALR3、CCL20、ADRA2B和CXCL6)。使用药物-基因相互作用数据库,pNETs治疗的候选药物包括3种表皮生长因子受体(EGFR)抑制剂(卡奈替尼、厄洛替尼、WZ-4-145),以及其他细胞信号通路抑制剂,如AG-592、阿卡波糖、氯尼达明、阿扎胞苷、rottlerin和HU-211。
利用现有的遗传图谱数据,基于差异表达基因确定了pNETs治疗的潜在候选药物。这些结果可能有助于集中精力寻找具有治疗效果的靶向药物来治疗pNETs患者。